Diagnostic performance is comparable to fluorine 18 fluorodeoxyglucose PET/CT in diagnosing pulmonary lesions.
Magnetic resonance imaging is comparable to fluorine 18 fluorodeoxyglucose PET/CT in determining if pulmonary lesions are malignant or benign, according to a study published in the journal Radiology.
Researchers from Brazil, the United States, and the United Kingdom performed a literature meta-analysis to compare how the diagnostic performance of fluorine 18 fluorodeoxyglucose PET/CT and diffusion-weighted (DW) MRI differed in determining malignant and benign pulmonary nodules and masses.
The researchers focused on studies that where DW MRI and PET/CT were performed in the entire study population:
The pooled sensitivities, specificities, diagnostic odds ratios, and areas under the receiver operating characteristic curve (AUCs) for PET/CT and DW MRI were determined.
The results showed that the 37 studies that met the inclusion criteria and a total of 4,224 participants and 4,463 lesions; 3,090 of the lesions were malignant (69.2%).
Related article: Study: In-Hospital MRIs Could Be Wasteful
The primary analysis of the 6 joint DW MRI and PET/CT studies showed that DW MRI had a pooled sensitivity of 83% and specificity of 91%, compared with a pooled sensitivity of 78% and specificity of 81% for PET/CT. DW MRI yielded an AUC of 0.93 versus 0.86 for PET/CT. The diagnostic odds ratio of DW MRI (50) was superior to that of PET/CT (15).
The researchers concluded that the diagnostic performance of diffusion-weighted MRI was comparable or superior to that of fluorine 18 fluorodeoxyglucose PET/CT when differentiating between malignant and benign pulmonary lesions.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.